

Oncology


Annual Report 2023 Fact Sheet

We are leading a revolution in oncology to redefine cancer care. Our ambition is to follow the science to discover, develop and deliver life-changing treatments that transform outcomes and increase the potential for cures.

Therapy area world market (MAT Q3-23)

\$187.0bn

Annual worldwide market value



- Small molecule targeted agents **\$56.2bn**
- Immune checkpoint inhibitors **\$45.1bn**
- Monoclonal antibodies (mAbs) **\$40.0bn**
- Chemotherapy **\$23.3bn**
- Hormonal therapies **\$17.7bn**
- PARP inhibitors **\$3.5bn**
- Other oncology therapies **\$1.0bn**

Source: IQVIA. AstraZeneca focuses on specific segments within this overall therapy area market. Oncology Therapy Area submarket totals (\$186.8bn) do not sum up exactly to the Therapy Area total (\$187.0bn) due to rounding.

Total Revenue

\$18,447m

Up 19%

(21% at CER)

Unmet medical need and AstraZeneca in 2023

10 markets

AstraZeneca had ten major market approvals across six medicines, and a new medicine approved for the first time.

2nd

Cancer is the second leading cause of death worldwide.

9+ve

We also had nine positive Phase III trial readouts across tumour types including the first positive results for a potential new medicine in lung and breast cancers.

16.3m

By 2040, cancer is expected to account for 16.3 million deaths annually across the globe.

>30m

The global burden of cancer is expected to grow, with over 30 million newly diagnosed patients estimated by 2040. Two-thirds of those patients are expected to be in low-to-middle income countries.

